Relmada Therapeutics Raises $100 Million to Advance Oncology and CNS Pipeline
核心洞察
Relmada Therapeutics completed a $100 million underwritten offering of common stock and pre-funded warrants to fund clinical development of its oncology (搜索) and central nervous system therapies.
The clinical-stage biotechnology company will use proceeds for regulatory studies, product development, and potential acquisitions to advance lead candidates NDV-01 and sepranolone.
Major institutional investors including Janus Henderson, Ferring Ventures, and OrbiMed (搜索) participated in the offering, demonstrating strong investor confidence in the company's pipeline.
Relmada Therapeutics, a clinical-stage biotechnology company developing innovative therapies for oncology (搜索) and central nervous system conditions (搜索), has successfully completed a $100 million underwritten offering to fund advancement of its therapeutic pipeline. The Coral Gables, Florida-based company priced 40,142,000 shares of common stock at $2.20 per share and pre-funded warrants for up to 5,315,000 shares at $2.199 per warrant.
Strong Institutional Support Drives Funding Success
The offering attracted significant institutional investment from prominent healthcare-focused funds, including Janus Henderson Investors (搜索), Ferring Ventures SA (搜索), Squadron Capital Management, Marshall Wace, Spruce Street Capital, OrbiMed (搜索), Columbia Threadneedle Investments, and Driehaus Capital Management. This diverse investor base reflects confidence in Relmada's clinical development strategy and pipeline potential.
Jefferies (搜索) and Leerink Partners (搜索) served as joint book-running managers for the offering, with Mizuho acting as book-runner. The transaction closed on November 5, 2025, providing immediate access to capital for the company's development programs.
Strategic Use of Proceeds for Pipeline Advancement
Relmada plans to deploy the net proceeds alongside existing cash, cash equivalents, and short-term investments for multiple strategic initiatives. The company will prioritize clinical studies required for regulatory approvals and implementation of adequate systems and controls to support the approval process.
The funding will also support further development of Relmada's product candidates, with particular focus on lead candidates NDV-01 and sepranolone, which are currently advancing through mid-stage clinical development. These programs target significant unmet medical needs in oncology (搜索)-related and central nervous system conditions (搜索).
Expansion and Acquisition Strategy
Beyond internal development, Relmada intends to use proceeds for strategic investments and acquisitions of companies with synergistic or complementary technologies. The company plans to pursue licensing activities related to current and future product candidates, as well as investments in emerging technologies that could enhance its therapeutic platform.
This capital raise positions Relmada to accelerate its clinical programs while maintaining flexibility to pursue external opportunities that could strengthen its pipeline or expand its technological capabilities. The company's focus on transformative therapies for oncology (搜索) and CNS conditions aligns with areas of significant unmet medical need and commercial opportunity.